NCT06660433 (PROMPT-LTC) is a NA clinical trial of Point-of-care respiratory test platform in Outbreaks, sponsored by Michael Garron Hospital.

Who is sponsoring NCT06660433?

NCT06660433 is sponsored by Michael Garron Hospital.

What drugs are being tested in NCT06660433?

Interventions in NCT06660433: Point-of-care respiratory test platform, Existing respiratory virus testing platform.

Is NCT06660433 still recruiting?

NCT06660433 is currently recruiting now. Last updated 2 December 2025.

Last reviewed 2025-12-02 · How we verify

NCT06660433: PROMPT-LTC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Respiratory Outbreak Mitigation in Long-Term Care Using Point-of-Care Testing

Recruiting now NA Last updated 2 December 2025

What this trial tests

NA trial testing Point-of-care respiratory test platform in Outbreaks in 24 participants. Currently enrolling.

Timeline

11 November 2024

Primary endpoint
30 May 2025

31 March 2026

Quick facts

Lead sponsor	Michael Garron Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	24
Start date	11 November 2024
Primary completion	30 May 2025
Estimated completion	31 March 2026
Sites	2 locations across Canada

Drugs / interventions tested

Point-of-care respiratory test platform
Existing respiratory virus testing platform

Conditions studied

Outbreaks — all drugs for Outbreaks →

Sponsor

Michael Garron Hospital

Who can join

Eligibility, any sex, with Outbreaks. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Outbreaks of seasonal respiratory viruses can spread rapidly in long-term care homes. Timely results for diagnostic tests remains a challenge for respiratory viruses due to the logistics of using a reference laboratory with delays leading to missed opportunities to implement virus-specific control measures to interrupt transmission resulting in larger outbreaks. Use of a point-of-care testing platform is a potential solution that provides faster results, but it is uncertain whether this translates into benefits for long-term care residents. This trial aims to assess whether rapid test results for respiratory pathogens (Influenza, Coronavirus disease of 2019 (COVID-19) and Respiratory Syncytial Virus) can impact the number and size of respiratory virus outbreaks in long-term care homes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Michael Garron Hospital trials

Trials by the same sponsor.

NCT07266753 — Comparison of Oral Antibiotics For Bone Infections of the Leg and Foot · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06660433 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michael Garron Hospital
Last refreshed: 2 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06660433.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing